Anti-alkaline phosphatase antibody positive myasthenia gravis. 2007

Tetsuro Konishi, and Kiyoe Ohta, and Kazuhiro Shigemoto, and Mitsuhiro Ohta
Department of Neurology, National Hospital Organization Utano National Hospital, 8, Ondoyama-cho, Narutaki, Ukyo-ku, Kyoto 616-8255, Japan. konishi@unh.hosp.go.jp

Anti-alkaline phosphatase antibody (AP Ab) was specific in 9% of 249 anti-acetylcholine receptor (AChR) Ab-positive myasthenia gravis (MG) (SPMG) patients but not in patients with AChR Ab-negative MG (SNMG), other neurological and immunological diseases, or healthy volunteers. No cross-reactivity and no significant titer correlation were found between AP Ab and AChR Ab. We confirmed immunologically by radioimmunoassay and western blot analysis the presence of antibodies directed against AP. AP Ab-positive SPMG patients were characterized clinically as having female predominance and a more severe form of generalized MG than AP Ab-negative SPMG patients, and about half required artificial ventilation at maximum severity. AP Ab's pathogenic role in MG is yet unclarified, but our findings show AP to be a novel antigen among the various autoantigens present in MG patients and in whom AP Ab may modify clinical symptoms.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D011950 Receptors, Cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology. ACh Receptor,Acetylcholine Receptor,Acetylcholine Receptors,Cholinergic Receptor,Cholinergic Receptors,Cholinoceptive Sites,Cholinoceptor,Cholinoceptors,Receptors, Acetylcholine,ACh Receptors,Receptors, ACh,Receptor, ACh,Receptor, Acetylcholine,Receptor, Cholinergic,Sites, Cholinoceptive
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Tetsuro Konishi, and Kiyoe Ohta, and Kazuhiro Shigemoto, and Mitsuhiro Ohta
September 2011, Orvosi hetilap,
Tetsuro Konishi, and Kiyoe Ohta, and Kazuhiro Shigemoto, and Mitsuhiro Ohta
May 2024, Brain and nerve = Shinkei kenkyu no shinpo,
Tetsuro Konishi, and Kiyoe Ohta, and Kazuhiro Shigemoto, and Mitsuhiro Ohta
January 2015, Internal medicine (Tokyo, Japan),
Tetsuro Konishi, and Kiyoe Ohta, and Kazuhiro Shigemoto, and Mitsuhiro Ohta
October 2010, The Journal of the Association of Physicians of India,
Tetsuro Konishi, and Kiyoe Ohta, and Kazuhiro Shigemoto, and Mitsuhiro Ohta
June 2015, Journal of neuroimmunology,
Tetsuro Konishi, and Kiyoe Ohta, and Kazuhiro Shigemoto, and Mitsuhiro Ohta
March 2011, Rinsho shinkeigaku = Clinical neurology,
Tetsuro Konishi, and Kiyoe Ohta, and Kazuhiro Shigemoto, and Mitsuhiro Ohta
May 2006, Journal of neurology,
Tetsuro Konishi, and Kiyoe Ohta, and Kazuhiro Shigemoto, and Mitsuhiro Ohta
January 2024, Brain and nerve = Shinkei kenkyu no shinpo,
Tetsuro Konishi, and Kiyoe Ohta, and Kazuhiro Shigemoto, and Mitsuhiro Ohta
December 2023, Rinsho shinkeigaku = Clinical neurology,
Tetsuro Konishi, and Kiyoe Ohta, and Kazuhiro Shigemoto, and Mitsuhiro Ohta
July 2009, Rinsho shinkeigaku = Clinical neurology,
Copied contents to your clipboard!